Arcutis reports 122% revenue growth for ZORYVE in Q3 2025
PositiveFinancial Markets

Arcutis has announced an impressive 122% revenue growth for its product ZORYVE in the third quarter of 2025. This significant increase highlights the product's strong market performance and growing acceptance among healthcare providers and patients. Such growth not only reflects the company's successful strategies but also indicates a rising demand for effective dermatological treatments, which is crucial for the company's future prospects.
— Curated by the World Pulse Now AI Editorial System










